Skip to content

Dose-finding for dobutamine during transitional circulation in the very preterm infant

Status
Recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-504915-34-00
Acronym
NeoCirc-002 TRIAL
Enrollment
30
Registered
2023-06-29
Start date
2024-06-20
Completion date
Unknown
Last updated
2025-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonates with haemodynamic insufficiency

Brief summary

Short-term PD endpoint: Minimum dobutamine dose to reach and maintain an SVC flow above 55 ml/k/min on an echocardiogram performed at 1 and 3 hours after effective infusion of the allocated dose [A].

Detailed description

Proportion of neonates achieving and maintaining a clinically acceptable haemodynamic status [B] with the dobutamine infusion alone in the first 72 hours from birth., Absolute and relative frequencies of adverse events (AEs) and severe adverse events (SAEs), to be recorded and compared between groups, To determine the correlation between PK and PD.

Interventions

DRUGDobutamine Generis 12.5 mg/mL Solution for Infusion

Sponsors

Hospital Universitario La Paz
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
0 Years to 17 Years

Design outcomes

Primary

MeasureTime frame
Short-term PD endpoint: Minimum dobutamine dose to reach and maintain an SVC flow above 55 ml/k/min on an echocardiogram performed at 1 and 3 hours after effective infusion of the allocated dose [A].

Secondary

MeasureTime frame
Proportion of neonates achieving and maintaining a clinically acceptable haemodynamic status [B] with the dobutamine infusion alone in the first 72 hours from birth., Absolute and relative frequencies of adverse events (AEs) and severe adverse events (SAEs), to be recorded and compared between groups, To determine the correlation between PK and PD.

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026